PTC Therapeutics (PTCT) is down sharply after releasing top-line results from the 24-month interim analysis of the PIVOT-HD long-term extension study for votoplam in Huntington’s disease. The company highlighted signals of dose-dependent slowing of disease progression in Stage 2 patients versus an external matched natural-history cohort, but the market focused on the lack of clear statistical significance in the comparisons, weighing on sentiment. (ir.ptcbio.com)

PTC said the 10 mg dose indicated roughly 52% slowing and the 5 mg dose about 28% slowing on cUHDRS versus the external cohort, while noting the differences were not statistically significant (the 10 mg arm showed a trend level of significance). For traders, that combination—encouraging directional efficacy but ambiguous statistical proof—often triggers profit-taking and a “sell-the-news” move after a catalyst headline. (marketbeat.com)

In biotech, shares can fall even on “positive” results when the new dataset doesn’t materially de-risk the next step (such as confirmatory trial design, regulatory path, or probability of approval) or when the market had already priced in stronger evidence. Today’s decline fits that pattern: the update reinforces a dose-response signal, but investors are reassessing how persuasive an external-control comparison is without conventional statistical separation. (marketbeat.com)